Ivan Schréte
Fixed-dose combination sofosbuvir-ledipasvir makes a major contribution towards the successful treatment of patients
with chronic hepatitis C. Higher effectiveness with significantly shorter duration of treatment compared to the standard-
of-care treatment, as well as good tolerance of this interferon-free combination (with or without ribavirin) has
been confirmed by clinical studies in various patient groups. The studies included treatment-naive patients and unsuccessfully
treated patients at different stage of liver disease progression, including decompensated cirrhosis, before
and after liver transplantation as well as patients with HIV co-infection. Treatment effectiveness was also confirmed in
patients in whom the previous three-drug combination treatment with 1st generation protease inhibitors had failed.